Compounds > triazoles
Page last updated: 2024-08-24

triazoles and darunavir

triazoles has been researched along with darunavir in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (20.00)29.6817
2010's21 (70.00)24.3611
2020's3 (10.00)2.80

Authors

AuthorsStudies
Boffito, M; Mallon, PW; Winston, A1
Temesgen, Z1
Taéron, C1
Barber, T; Hughes, A; Nelson, M1
Arribas, JR1
Aiuti, F; Esposito, A; Fantauzzi, A; Isgro, A; Leti, W; Mezzaroma, I; Pastori, D1
Abel, S; Davis, J; Hamlin, J; Hoetelmans, RM; Kakuda, TN; Mack, R; Ndongo, N; Petit, W; Ridgway, C; Schöller-Gyüre, M; Sekar, V; Tweedy, S1
Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J1
Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J1
Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C1
Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G1
Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A1
Lacombe, K; Surgers, L1
Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Montrucchio, C; Trentini, L1
Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB1
Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A1
Annaert, P; Augustijns, P; Fattah, S; Stappaerts, J1
Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E1
Ajassa, C; Ermocida, A; Lichtner, M; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V1
Bigoloni, A; Boeri, E; Castagna, A; Cavarelli, M; Galli, A; Mainetti, L; Nozza, S; Pignataro, AR; Sampaolo, M; Scarlatti, G; Tolazzi, M1
Baccarani, U; Bassetti, M; Bonora, S; Dal Zoppo, S; Della Siega, P; Delle Foglie, P; Giglio, O; Londero, A; Nasta, P; Pea, F; Righi, E; Villa, G1
Ahmed, N; Ainsworth, J; Okoli, C1
Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN1
Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL1
Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X1
Álvarez, H; Llibre, JM; Yzusqui, M1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K1
Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ1
Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K1

Reviews

5 review(s) available for triazoles and darunavir

ArticleYear
The clinical pharmacology of antiretrovirals in development.
    Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:3

    Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles

2006
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    The Journal of infection, 2008, Volume: 57, Issue:1

    Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles

2008
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 12

    Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles

2008
Hepatoxicity of new antiretrovirals: a systematic review.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

    Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles

2013
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
    AIDS reviews, 2018, Volume: 20, Issue:3

    Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load

2018

Trials

6 trial(s) available for triazoles and darunavir

ArticleYear
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5

    Topics: Adolescent; Adult; Cyclohexanes; Darunavir; Drug Interactions; Female; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Young Adult

2011
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:9

    Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult

2013
Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.
    AIDS (London, England), 2016, 08-24, Volume: 30, Issue:13

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles

2016
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2017
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. HIV, 2018, Volume: 5, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load

2018
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    The lancet. HIV, 2020, Volume: 7, Issue:1

    Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult

2020

Other Studies

19 other study(ies) available for triazoles and darunavir

ArticleYear
The latest in antiretroviral therapy.
    Drug news & perspectives, 2006, Volume: 19, Issue:8

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles

2006
[New drugs for HIV infection].
    Revue de l'infirmiere, 2008, Issue:138

    Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles

2008
[Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].
    Le infezioni in medicina, 2009, Volume: 17, Issue:3

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunocompetence; Interleukin-2; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Triazoles; Viral Load

2009
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:3

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles

2012
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
    PLoS pathogens, 2012, Volume: 8, Issue:6

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia

2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
    AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14

    Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load

2012
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles

2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles

2013
Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Female; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Failure; Triazoles; Viral Load

2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Journal of acquired immune deficiency syndromes (1999), 2013, Oct-01, Volume: 64, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load

2013
Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model.
    Xenobiotica; the fate of foreign compounds in biological systems, 2014, Volume: 44, Issue:6

    Topics: Animals; Area Under Curve; Caco-2 Cells; Cell Membrane Permeability; Cells, Cultured; Darunavir; Hepatobiliary Elimination; Hepatocytes; Humans; Infusions, Intravenous; Intestinal Elimination; Liver; Male; Models, Animal; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Triazoles

2014
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    HIV medicine, 2014, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles

2014
Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.
    The new microbiologica, 2014, Volume: 37, Issue:2

    Topics: Anti-HIV Agents; Apoptosis; Cells, Cultured; Cyclohexanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Maraviroc; Neutrophils; Sulfonamides; Triazoles

2014
Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:12

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL5; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Envelope Protein gp120; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Oxazines; Peptide Fragments; Phylogeny; Piperazines; Pyridones; Receptors, CCR5; Receptors, CXCR4; Ritonavir; Sulfonamides; Triazoles; Viral Load; Viral Tropism

2014
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:1

    Topics: Anti-Retroviral Agents; Coinfection; Cyclohexanes; Darunavir; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Triazoles

2015
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
    International journal of STD & AIDS, 2016, Volume: 27, Issue:4

    Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load

2016
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
    Journal of neurovirology, 2017, Volume: 23, Issue:6

    Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine

2017
Changes in weight and BMI with first-line doravirine-based therapy.
    AIDS (London, England), 2021, 01-01, Volume: 35, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2021
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
    The Journal of antimicrobial chemotherapy, 2021, 04-13, Volume: 76, Issue:5

    Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles

2021